Innocan Pharma Posts Strong Q1 2026 Results*, With Revenue Surging 29.7% to US$6.47M

Keyword: Drug Delivery

Publisher: PRNewswire

Published: May 27, 2026

HERZLIYA, Israel and CALGARY, AB, May 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusin… [+10192 chars]

Read Full Story ↗

Related Content

Related Story NeOnc Technologies (NTHI) Could Be Targeting A Challenging Market With A Different Strategy

Yahoo Entertainment
Related Story Clinical translation and landscape of stimuli-responsive nanomedicines and microscale therapeutics

Royal Society of Chemistry
Related Story Global Nasal Spray Market Projected to Hit USD 77.0 Billion by 2035, Fueled by 8.97% CAGR – SNS Insider

GlobeNewswire